Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.73 |
| ▸ | MAP3K7 | O43318 | 8/20 | 0.73 |
| ▸ | MAP4K2 | Q12851 | 8/20 | 0.73 |
| ▸ | ABL1 | P00519 | 5/20 | 0.67 |
| ▸ | KDR | P35968 | 4/20 | 0.67 |
| ▸ | SRC | P12931 | 4/20 | 0.67 |
| ▸ | MAP3K20 | Q9NYL2 | 4/20 | 0.67 |
| ▸ | RET | P07949 | 4/20 | 0.67 |
| ▸ | FES | P07332 | 3/20 | 0.67 |
| ▸ | FER | P16591 | 3/20 | 0.67 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.67 |
| ▸ | CSK | P41240 | 3/20 | 0.67 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.67 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.67 |
| ▸ | BRAF | P15056 | 2/20 | 0.67 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.67 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.67 |
| ▸ | RAF1 | P04049 | 2/20 | 0.67 |
| ▸ | LYN | P07948 | 2/20 | 0.67 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3880675 | 0.94 | MAPK14 (0.71) | MAPK14MAP3K7MAP4K2ABL1KDR | |
| SCHEMBL14690370 | 0.91 | MAP3K7 (0.85) | MAPK14MAP3K7MAP4K2ABL1KDR | |
| SCHEMBL30692256 | 0.91 | MAP3K7 (0.85) | MAPK14MAP3K7MAP4K2ABL1KDR | |
| SCHEMBL12999177 | 0.89 | MAPK14 (0.58) | MAPK14MAP3K7MAP4K2ABL1KDR | |
| SCHEMBL2851874 | 0.88 | SRC (0.67) | MAPK14MAP3K7MAP4K2ABL1KDR | |
| SCHEMBL23353598 | 0.85 | MAP3K7 (0.66) | MAPK14MAP3K7MAP4K2ABL1KDR | |
| SCHEMBL3880678 | 0.85 | MAPK14 (0.60) | MAPK14MAP3K7MAP4K2ABL1KDR | |
| SCHEMBL4791338 | 0.85 | MAP3K7 (0.62) | MAPK14MAP3K7MAP4K2ABL1KDR | |
| SCHEMBL14690002 | 0.84 | MAP3K7 (1.00) | MAPK14MAP3K7MAP4K2ABL1SRC | |
| SCHEMBL30692261 | 0.84 | MAP3K7 (1.00) | MAPK14MAP3K7MAP4K2ABL1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592433-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-11-26 | — | — | US | claimed |
| US-20100324062-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-12-23 | — | — | US | claimed |
| US-20100130476-A1 | COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-05-27 | — | — | US | claimed |
| US-8592433-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-11-26 | — | — | US | disclosed |
| US-20100324062-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-12-23 | — | — | US | disclosed |
| US-20100324062-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-12-23 | — | — | US | disclosed |
| US-20100130476-A1 | COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-05-27 | — | — | US | disclosed |
| WO-2010056907-A2 | COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-1940844-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-09-30 | — | — | EP | disclosed |
| EP-1940844-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-09-30 | — | — | EP | disclosed |
| WO-2007053343-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324062-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | SYK, SRC, FYN | MAPK14 303/4885MAP3K7 50/4885MAP4K2 38/4885 |
| US-20100130476-A1 | COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION | IAPP, PNLIP, GPR119 | MAPK14 1692/4885MAP3K7 1968/4885MAP4K2 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.